*Denotes an adverse reaction that has been reported in association with a fatal outcome.
1% difference in discontinuation rate due to ARs in all study therapy was observed between treatment arms1:
An increased incidence of febrile neutropenia was observed for Asian patients in both treatment arms compared with patients of other races and from other geographic regions.
The majority of diarrhea episodes occurred during the first 3 cycles of treatment.
Docetaxel should be administered for a minimum of 6 cycles.
Median follow-up was 50 months.1
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.